DOCSLIB.ORG

Biopharmaceutical Industry Speakers List Cost and Value of Medicines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biopharmaceutical Industry Speakers List Cost and Value of Medicines Biopharmaceutical Industry Speakers List Cost and Value of Medicines PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA About the Speakers List The Biopharmaceutical Industry Speakers List contains names of executives at the Pharmaceutical Research and Manufacturers of America (PhRMA) and its member companies available to participate in events and panel discussions on the cost and value of prescription medicines. A photo, biography and contact information is available for each speaker. There is no fee associated with any speaking engagement. Parties interested in securing a speaker should contact these individuals directly to discuss their participation. PhRMA and its member companies will attempt to accommodate all requests, but cannot guarantee participation. For questions or more information, please contact the PhRMA Newsroom at [email protected] or call 202-835-3460. BIOPHARMACEUTICAL INDUSTRY SPEAKERS LIST 2 Available Speakers PhRMA JEFFREY BOND LORI M. REILLY, J.D. Senior Vice President, Advocacy Executive Vice President, Policy and Research Washington, D.C. Washington, D.C. JENNIFER BRYANT JAMES “MIT” M. SPEARS, J.D. Senior Vice President, Policy and Research General Counsel, Washington, D.C. Executive Vice President, Legal Washington, D.C. RANDY BURKHOLDER Vice President, Policy and Research STEPHEN J. UBL Washington, D.C. President and Chief Executive Officer Washington, D.C. WILLIAM “BILL” CHIN, M.D. Chief Medical Officer and Executive Vice MICHAEL YBARRA, M.D. President, Science and Regulatory Affairs Senior Director, Alliance Development Washington, D.C. Washington, D.C. JOSEPHINE “JOSIE” C. MARTIN ROBERT ZIRKELBACH Executive Vice President, Public Affairs Senior Vice President, Communications Washington, D.C. Washington, D.C. PhRMA Member Companies AbbVie LATIF AKINTADE, M.D., MBA JEFFREY R. STEWART Vice President, Global Market Access Vice President, U.S. Commercial Operations North Chicago, Illinois North Chicago, Illinois SCOTT BRUN, M.D. JAMES P. SULLIVAN, PH.D. Vice President, Pharmaceutical Development Vice President, Discovery North Chicago, Illinois North Chicago, Illinois BIOPHARMACEUTICAL INDUSTRY SPEAKERS LIST 3 PhRMA Member Companies Amgen Inc. KENTON STEWART Vice President, Health Systems RESHMA KEWALRAMANI, M.D. FASN Northbrook, Illinois Head, U.S. Medical Organization Vice President, Global Medical AstraZeneca Thousand Oaks, California CHRISTINE BLOOMQUIST, J.D. MARK MORGAN Vice President, Executive Director, U.S. Commercial Federal Government Affairs and Policy Operations Washington, D.C. Thousand Oaks, California DAVE FREDRICKSON JOSHUA J. OFMAN, M.D., MSHS Vice President, Specialty Care Senior Vice President, Global Value, Gaithersburg, Maryland Access and Policy Thousand Oaks, California PAUL HUDSON President, U.S. and Executive Vice President, MARTIN ZAGARI, M.D. North America Vice President, Global Health Economics Wilmington, Delaware Thousand Oaks, California Bayer Astellas PHILIP BLAKE JEFFREY BLOSS, M.D. President, U.S. and Head of Americas Region, Senior Vice President, Medical Affairs, Pharmaceuticals Americas Whippany, New Jersey Northbrook, Illinois SHANNON CAMPBELL SHONTELLE DODSON, PHARM.D. Vice President and General Manager, Oncology Vice President, Medical Affairs, Global Whippany, New Jersey Northbrook, Illinois HABIB DABLE MARTIN GOLDEN, J.D., MBA President, U.S. Pharmaceuticals Vice President, Government Affairs Whippany, New Jersey Northbrook, Illinois KEVIN O’LEARY WALT JOHNSON Vice President, Vice President, U.S. Marketing and Strategic Pricing and Reimbursement Strategic New Product Planning Whippany, New Jersey Northbrook, Illinois MARK REISENAUER Vice President, Oncology Sales and Marketing Northbrook, Illinois BIOPHARMACEUTICAL INDUSTRY SPEAKERS LIST 4 PhRMA Member Companies Biogen Inc. Bristol-Myers Squibb DAVID MILLER, PH.D. Company Senior Vice President, Global Market Access CHRISTOPHER BOERNER, PH.D. Cambridge, Massachusetts President and Head, U.S. Commercial Operations ALFRED SANDROCK, JR., M.D., PH.D. Plainsboro, New Jersey Executive Vice President, Neurology Discovery and Development Center, Neurodegeneration MURDO GORDON Therapeutic Area and Chief Medical Officer Senior Vice President and Head, Cambridge, Massachusetts Worldwide Markets Princeton, New Jersey KATHLEEN TREGONING Senior Vice President, Corporate Affairs FOUAD NAMOUNI, M.D. Washington, D.C. Head, Medical Princeton, New Jersey Boehringer Ingelheim Pharmaceuticals, Inc. KEVIN TRAPP Head, Product, Portfolio and Access Strategy JAMES BAXTER, PHARM.D., PH.D. Princeton, New Jersey Senior Vice President, Development Ridgefield, Connecticut Celgene Corporation PAUL FONTEYENE MARK ALLES President and Chief Executive Officer President and Chief Operating Officer Ridgefield, Connecticut Summit, New Jersey DAVID S. MEMEL, M.D., M.S., MBA RICHARD BAGGER Vice President, Health Economics Executive Vice President, Corporate Affairs and Outcomes Research and Market Access Ridgefield, Connecticut Summit, New Jersey JOANNE PALMISANO, M.D., FACP JOEL BEETSCH, PH.D. Vice President, Regulatory Affairs Vice President, Patient Advocacy Ridgefield, Connecticut Summit, New Jersey BRIAN GILL Vice President, Corporate Communications Summit, New Jersey BIOPHARMACEUTICAL INDUSTRY SPEAKERS LIST 5 PhRMA Member Companies Eli Lilly and Company CAROLINE DE MARCO Vice President, Regional Accounts ALEX AZAR Philadelphia, Pennsylvania President, Lilly USA Indianapolis, Indiana JAMEY MILLAR Senior Vice President, Managed Markets ENRIQUE CONTERNO and Government Affairs Senior Vice President and President, Research Triangle Park, North Carolina Lilly Diabetes Indianapolis, Indiana Horizon Pharma NEWTON F. CRENSHAW JEFFREY D. KENT, M.D., FACG Vice President, Lilly Oncology, U.S. and Canada Senior Vice President, Medical Affairs Indianapolis, Indiana and Clinical Outcomes Deerfield, Illinois SHERRY MARTIN, M.D. Vice President, Clinical Development JEFFREY W. SHERMAN, M.D., FACP Operations, Diabetes Chief Medical Officer and Executive Indianapolis, Indiana Vice President Deerfield, Illinois DAVE RICKS Senior Vice President and President, Bio-Medicines Janssen Pharmaceutical Indianapolis, Indiana Companies of Johnson & Johnson EMD Serono, Inc. ANASTASIA G. DAIFOTIS, M.D. MICHAEL J. RUGGIERO Chief Scientific Officer, Janssen Vice President, Titusville, New Jersey U.S. Government Affairs and Policy Washington, D.C. ELIZABETH FOWLER, PH.D., J.D. Vice President, Global Health Policy, GlaxoSmithKline plc Johnson & Johnson Washington, D.C. JACK BAILEY President, U.S. Pharmaceuticals BLASINE PENKOWSKI Research Triangle Park, North Carolina Chief Strategic Customer Officer, Janssen Titusville, New Jersey TANISHA CARINO, PH.D. Vice President, U.S. Public Policy Washington, D.C. BIOPHARMACEUTICAL INDUSTRY SPEAKERS LIST 6 PhRMA Member Companies Mallinckrodt ROBERT SPURR U.S. Country Head and Vice President, MATTHEW HARBAUGH Patient Access and Health Policy Senior Vice President East Hanover, New Jersey and Chief Financial Officer St. Louis, Missouri Novo Nordisk, Inc. HUGH O’NEILL TODD HOBBS, M.D. Senior Vice President and President, Vice President, Chief Medical Officer, Autoimmune and Rare Diseases North America St. Louis, Missouri Plainsboro, New Jersey STEVEN ROMANO, M.D. CURT G. OLTMANS Senior Vice President Corporate Vice President and General Counsel and Chief Scientific Officer Plainsboro, New Jersey St. Louis, Missouri SEAN PHILLIPS Merck & Co., Inc. Vice President, Managed Markets Plainsboro, New Jersey PATRICK DAVISH Associate Vice President, Orexigen Therapeutics, Inc. Global Market Access - Global Pricing Upper Gwynedd, Pennsylvania MICHAEL A. NARACHI President and Chief Executive Officer PATRICK MAGRI La Jolla, San Diego, California Senior Vice President, Hospital and Specialty Business Unit Upper Gwynedd, Pennsylvania Otsuka America Pharmaceutical, Inc. Novartis Pharmaceuticals JOHN BARDI Corporation Vice President, Government Affairs Rockville, Maryland WILLIAM HINSHAW Executive Vice President, U.S. Oncology ROB LAVERTY East Hanover, New Jersey Vice President, Market Access Princeton, New Jersey CHRISTI SHAW U.S. Country Head, President BOB OLIVER East Hanover, New Jersey President & Chief Operating Officer Princeton, New Jersey BIOPHARMACEUTICAL INDUSTRY SPEAKERS LIST 7 PhRMA Member Companies Pfizer Inc. ELIAS ZERHOUNI, M.D. President, Global Research & Development KIRSTEN AXELSEN Paris, France, and Bethesda, Maryland Vice President, Global Policy New York, New York Takeda Pharmaceuticals GENO GERMANO USA, Inc. Group President, RICHARD “RICK” ASCROFT Global Innovative Pharma Business Vice President, Managed Markets New York, New York and Government Affairs Deerfield, Illinois JUSTIN MCCARTHY, J.D. Senior Vice President, RAMONA SEQUEIRA Global Policy and International Affairs President, U.S. Business Unit New York, New York Deerfield, Illinois Sanofi PAUL CHEW, M.D. Global Chief Medical Officer Bridgewater, New Jersey, and Paris, France SURESH KUMAR Executive Vice President, External Affairs Paris, France DAVID MEEKER, M.D. Executive Vice President and Head, Sanofi Genzyme Cambridge, Massachusetts JEZ MOULDING U.S. Country Chair North America Region Head, Diabetes & Cardiovascular Business Unit Bridgewater, New Jersey GARY J. NABEL, M.D., PH.D. Chief Scientific Officer, Global Research and Development Paris, France, and Bethesda, Maryland BIOPHARMACEUTICAL INDUSTRY SPEAKERS LIST 8 Jeffrey Bond PhRMA Senior Vice President, State Advocacy Washington, DC With over 30 years’ experience in the member of Patient Assistance Foundation
Load more

Recommended publications
  • Drug Safety Oversight Board Members
    April 29, 2021 Drug Safety Oversight Board (DSOB) Roster Chair • Douglas Throckmorton, M.D., Deputy Director for Regulatory Programs Center for Drug Evaluation and Research Executive Director • Terry Toigo, R.Ph, MBA Associate Director for Drug Safety Operations, Center for Drug Evaluation and Research Food and Drug Administration Center for Drug Evaluation and Research (CDER) Office of the Center Director (OCD) Primary Member: • Robert Temple, M.D., Deputy Director for Clinical Science Office of New Drugs (OND) Primary Member: • Mary Thanh Hai, M.D., Deputy Director, Office of New Drugs Alternate Members: • Peter Stein, M.D., Director, Office of New Drugs • Ellis Unger, M.D., Director, Office of Office of Cardiology, Hematology, Endocrinology, and Nephrology (OCHEN) Office of Medical Policy (OMP) Primary Member: • Jacqueline Corrigan-Curay, Director Alternate Member: • Leonard V. Sacks, Mgr. Supervisory Medical Officer Office of Generic Drugs (OGD) Primary Member: • Linda Forsyth, M.D., Division of Clinical Review Alternate Member: • Vacant Office of Surveillance and Epidemiology (OSE) Primary Members: • Mark I. Avigan, M.D., Associate Director for Critical Path Initiatives • Judy Zander, M.D., Director, Office of Pharmacoviligance and Epidemiology (OPE) Alternate Members: • Gerald DalPan, M.D., M.H.S., Director, OSE • S. Chris Jones, Deputy Director, Division of Pharmacovigilance (DPV) II • Judy Staffa, Ph.D., R.Ph., Associate Director for Public Health Initiatives -Page 1 of 4- April 29, 2021 • Cynthia LaCivita, R.Ph, Director, Division
    [Show full text]
  • When Mentoring Matters
    careers & recruitment People Recent moves of note in and around the biotech and pharma industries. over 20 years of experience in the pharma Clinical-stage biopharma Humanigen has announced the industry, including significant gene therapy appointment of Adrian Kilcoyne (photo) to the newly created translational and development expertise. role of chief medical officer. He brings leadership experience Reape was most recently chief medical from multinational pharma and biotech companies and a officer at Spark Therapeutics. strong clinical background in internal medicine and public health medicine, having recently served as vice president of Clinical-stage precision medicine oncology global medical affairs, head of evidence generation company Relay Therapeutics has named and external alliances at AstraZeneca. Patrick Riley senior vice president of “Dr. Kilcoyne’s experience and knowledge in multiple areas, including COVID-19, artificial intelligence. Riley has over a CAR-T and other oncology clinical development areas, medical affairs, regulatory affairs, decade of data science and machine learning evidence generation, health economics and partnering, gives him a unique insight that can experience from Google, initially in web be leveraged towards Humanigen’s COVID-19, acute GvHD, CAR-T and other oncology search and user behavior analysis and programs with lenzilumab and ifabotuzumab,” said Humanigen CEO Cameron Durrant. later as a principal engineer and senior “In addition, Adrian’s leadership in the external alliances arena will be instrumental in researcher on the Google Accelerated helping guide the progress of Humanigen’s pipeline and potential commercialization.” Science team. In addition, Relay has appointed Charles Ferté, formerly AstraZeneca’s senior director and global project leader of oncology R&D, as its Laura Carter has been appointed CSO of Precision metagenomics company vice president and lead for RLY-4008, a Gossamer Bio, succeeding Luisa Salter-Cid.
    [Show full text]
  • Public Health Act
    Province of Alberta PUBLIC HEALTH ACT Revised Statutes of Alberta 2000 Chapter P-37 Current as of June 17, 2021 Office Consolidation © Published by Alberta Queen’s Printer Alberta Queen’s Printer Suite 700, Park Plaza 10611 - 98 Avenue Edmonton, AB T5K 2P7 Phone: 780-427-4952 Fax: 780-452-0668 E-mail: [email protected] Shop on-line at www.qp.alberta.ca Copyright and Permission Statement Alberta Queen's Printer holds copyright on behalf of the Government of Alberta in right of Her Majesty the Queen for all Government of Alberta legislation. Alberta Queen's Printer permits any person to reproduce Alberta’s statutes and regulations without seeking permission and without charge, provided due diligence is exercised to ensure the accuracy of the materials produced, and Crown copyright is acknowledged in the following format: © Alberta Queen's Printer, 20__.* *The year of first publication of the legal materials is to be completed. Note All persons making use of this consolidation are reminded that it has no legislative sanction, that amendments have been embodied for convenience of reference only. The official Statutes and Regulations should be consulted for all purposes of interpreting and applying the law. Amendments Not in Force This consolidation incorporates only those amendments in force on the consolidation date shown on the cover. It does not include the following amendments: RSA 2000 cP-37 s77 repeals ss1(1)(e.1) and (2), 33(2.1) and (2.2), 52.6(1.1)(c) and (1.2), 52.61, 52.92 to 52.992, 53(4.2) to (4.4), 53.1 to 53.4, 66(2)(r), 76.
    [Show full text]
  • April 7, 2021 Message from Chief Medical Officer on COVID-19
    From: Chief Medical Officer Subject: Message from Chief Medical Officer on COVID-19 Vaccine Availability Date: Wednesday, April 7, 2021 6:08:49 PM Attachments: image001.png April 7, 2021 Message from Chief Medical Officer on COVID-19 Vaccine Availability Dear Colleagues, Earlier this week, President Biden announced the timeline for all U.S. adults to be eligible for the COVID-19 vaccine was moved up to April 19, from the original goal of May 1. That means that in just over a week, any adult in our country who wants a vaccine will be eligible to register for one. This news brings us hope and encouragement that we are on the right path to defeat the pandemic. I want to provide as many resources as possible to help you navigate the various pathways for getting the vaccine. As a DHS employee, there are several roads to vaccination. Mission-essential, location-dependent (1A/1B) employees were provided an opportunity to receive the vaccine through our partnership with the Veterans Health Administration (VHA). Currently, 163 VA Medical Centers (VAMCs) across the country are scheduling and vaccinating those 1A/1B employees who opted in. DHS employees also have several options to locate vaccine opportunities in their communities through VaccineFinder.org or local retail pharmacies. NEW: All non-1A/1B DHS employees may present this designation letter to their local vaccine provider immediately as proof of priority eligibility to receive the COVID-19 vaccine as part of the Centers for Disease Control and Prevention’s Phase 1C (essential workforce) recommendation. Note: This designation letter is not for use as part of our VHA partnership, as the VAMCs are completing vaccinations for DHS 1A/1B colleagues only.
    [Show full text]
  • Global Health, Epidemiology and Genomics
    global health, epidemiology and genomics HEALTH CARE SYSTEMS ORIGINAL RESEARCH ARTICLE Competency of peripheral health workers in detection & management of common syndromic conditions under surveillance, North 24 Parganas, West Bengal, India, 2016: a cross-sectional study F. Debnath1,2*, T. Bhatnagar3, L. Sundaramoorthy3 and M. Ponnaiah3 1 Division of Epidemiology, ICMR-National Institute of Cholera and Enteric Diseases, Kolkata, West Bengal, India 2 Masters of Public Health Scholar, ICMR-National Institute of Epidemiology, Chennai, India 3 ICMR School of Public Health, ICMR-National Institute of Epidemiology, Chennai, India Global Health, Epidemiology and Genomics (2017), 2, e15, page 1 of 8. doi:10.1017/gheg.2017.13 Background Competency of peripheral health workers in the detection and management of common syndromic condi- tions is crucial as they are the first point of contact for the majority of the Indian population. Methods We measured the competency of auxiliary nurse midwives (ANMs), and factors associated with inadequate competency, in the detection and management of common conditions diarrhoea,̶ acute respiratory tract infection, fever, malaria through̶ a cross-sectional study using condition specific validated clinical vignettes and structured questionnaires. Results Out of 272 selected ANMs, 68% (95% CI 62–74%) were adequately competent. Factors independently associated with inadequate competency were unavailability of essential drugs in preceding month [adjusted odds ratio (AOR) = 1.95; 95% CI 1.1–3.5] and ever trained in integrated management of childhood illness (AOR = 2.4; 95% CI 1.4–4.1). Conclusion More than two third of the peripheral health workers were adequately competent to detect and manage com- mon conditions.
    [Show full text]
  • Washington, D.C. Update – September 2016
    GOVERNMENT RELATIONS AND PUBLIC POLICY September 2016 This is an advertisement. Washington, D.C. Update Clinton and Trump: A Policy Comparison This month, we have a special edition of the Baker Donelson Washington Update focusing on what to expect from the 45th President of the United States. Of course we are all waiting on the November election to find out whether that will be Secretary Hillary Clinton or Mr. Donald Trump; in the meantime, we will examine a number of the candidates’ statements, proposals and announced transition teams to get a sense of what we can expect when a new president is sworn into office on January 20, 2017. Here is what is included in this month’s Washington Update: • Taxes – Clinton and Trump Propose Diametrically Opposed Tax Plans • Trade and Investment – A Rare Area of Agreement on TPP • The Economy – Two Differing Ways to Grow the Economy and Create Shared Prosperity • Energy and Environment – Opposites on Oil, Gas and Coal; Potential Overlap in Nuclear Power • Health Care – The Fight Over the ACA Continues • Presidential Transition Teams Regarding the potential for a long-term budget and appropriations deal or the future of defense spending, other than a commitment by Secretary Clinton to provide “budgetary certainty to facilitate reforms and enable long-term planning,” these issues have not been meaningfully addressed by either campaign. For additional information regarding the current budget decisions, please see the Washington, D.C. Fall Preview in which we examined the FY17 appropriations process and discussed the future of defense policy with former Vice Chief of Staff of the Air Force retired General Carrol “Howie” Chandler.
    [Show full text]
  • MEI Pharma Announces the Retirement of Chief Medical Officer
    MEI Pharma Announces the Retirement of Chief Medical Officer Robert Mass and Promotion of Richard Ghalie to Chief Medical Officer SAN DIEGO, April 30, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the retirement of Robert Mass, M.D., MEI's chief medical officer. Dr. Mass joined the company in 2010 and will retire on May 3, 2021, after which he will continue to serve as a strategic advisor to the company. The Company also announced that Richard Ghalie, M.D., MEI's senior vice president, clinical development, has been promoted to chief medical officer. "Bob's contributions to MEI over his more than ten years at the company have been invaluable across our drug candidate pipeline, particularly in guiding the strategy and broad clinical development program for zandelisib, which will best be measured by the benefit these programs may ultimately provide to patients. I want to thank Bob for his dedication to MEI and his friendship over these past 10 years. We wish him the very best in his retirement and look forward to continued interaction through his advisory role," said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma. "I also welcome Richard stepping into his role as our new chief medical officer, a role for which he is very well suited, as evidenced by the significant progress in our zandelisib program under Richard's guidance and its progress with our partners at Kyowa Kirin towards zandelisib's planned new drug application for consideration by FDA for approval under the accelerated approval pathway." Dr.
    [Show full text]
  • Directory of State and Local Government
    DIRECTORY OF STATE AND LOCAL GOVERNMENT Prepared by RESEARCH DIVISION LEGISLATIVE COUNSEL BUREAU 2020 Table of Contents TABLE OF CONTENTS Please refer to the Alphabetical Index to the Directory of State and Local Government for a complete list of agencies. NEVADA STATE GOVERNMENT ORGANIZATIONAL CHART ............................................. D-9 CONGRESSIONAL DELEGATION ............................................................................................. D-13 DIRECTORY OF STATE GOVERNMENT CONSTITUTIONAL OFFICERS: Attorney General ........................................................................................................................ D-15 State Controller ........................................................................................................................... D-19 Governor ..................................................................................................................................... D-20 Lieutenant Governor ................................................................................................................... D-27 Secretary of State ........................................................................................................................ D-28 State Treasurer ............................................................................................................................ D-30 EXECUTIVE BOARDS ................................................................................................................. D-31 NEVADA SYSTEM OF HIGHER EDUCATION
    [Show full text]
  • 1 United States District Court for the Southern District
    Case 1:07-cv-12141-PBS Document 18-3 Filed 11/28/07 Page 1 of 167 UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF IOWA, CENTRAL DIVISION THE STATE OF IOWA, Plaintiff, v. ABBOTT LABORATORIES, INC., AGOURON PHARMACEUTICALS, INC., JURY TRIAL REQUESTED ALPHARMA, INC., ALZA CORPORATION, AMGEN, INC., ASTRAZENECA L.P., ASTRAZENECA PHARMACEUTICALS, LP., AVENTIS BEHRING L.L.C., COMPLAINT BARR LABORATORIES, INC., BAXTER INTERNATIONAL, INC., BAXTER HEALTHCARE CORPORATION, BAYER CORPORATION, BAYER PHARMACEUTICALS CORPORATION, BEN VENUE LABORATORIES, INC., BOEHRINGER INGELHEIM CORPORATION, BOEHRINGER INGELHEIM PHARMACEUTICALS, INC., BRISTOL-MYERS SQUIBB COMPANY, CENTOCOR, INC., CHIRON CORPORATION, DERMIK LABORATORIES, INC., DEY, INC., DEY, L.P., ELI LILLY AND COMPANY, EMD, INC., ENDO PHARMACEUTICALS, INC., ETHEX CORPORATION, ETHICON, INC., FOREST LABORATORIES, INC., FOREST PHARMACEUTICALS, INC. GENEVA PHARMACEUTICALS, GLAXOSMITHKLINE, PLC, GLAXOWELLCOME, INC., GREENSTONE, LTD., HOECHEST MARION ROIUSSEL, INC., HOFFMAN-LAROCHE, INC., 1 Case 1:07-cv-12141-PBS Document 18-3 Filed 11/28/07 Page 2 of 167 IMMUNEX CORPORATION, IVAX CORPORATION, IVAX PHARMACEUTICALS, INC., JANSSEN PHARMACEUTICA PRODUCTS, LP, JOHNSON & JOHNSON, KING PHARMACEUTICALS, INC., KING RESEARCH AND DEVELOPMENT, MCNEIL-PPC, INC., MEDIMMUNE, INC., MERCK & CO., INC., MONARCH PHARMACEUTICALS, INC., MYLAN LABORATORIES, INC., MYLAN PHARMACEUTICALS, INC., NOVARTIS PHARMACEUTICALS CORPORATION, NOVOPHARM USA, INC., ONCOLOGY THERAPEUTICS NETWORK CORP., ORTHO-MCNEIL PHARMACEUTICAL, INC.,
    [Show full text]
  • THE WESTFIELD LEADER 30-33 Degrees
    o o o X co ^a cr: < ia O - j E-i Today's weather: rain developing by evening. high 45-48 degrees, low THE WESTFIELD LEADER 30-33 degrees. ITte Leading and Most Widely Circulated Weekly Newspaper In Union County Second Clasa Postage Paid Published EIGHTY-FOURTH YEAR—-No. 32 at Weatfleld. N. J. WESTFIELD, NEW JERSEY, THURSDAY. MARCH 21, 1974 very Thurat 26 Pases—15 Cents Resident Named County Dems Registration Set County Group Back Levin For New.Fool INames School Board Appoints Director of State Division For Congress LD. Cards Mrs. Allen •TKENTON - Thomas A. mercial and residential The evening times for Mrs. Sally S. Allen, New Superintendent Kelly, of Westfield a North development projects in the The Union County validating cards for the recently re-elected to the Jersey banking executive, North Jersey area serviced Democratic Committee has Westfield Memorial Pool's Hoard of Educat ion here has Dr. Laurence F. Greene, who has been involved in by the Jersey City-based chosen Adam K, Levin of new season and for issuing Dr. William R. Manning, bank. Westfield to run . for been elected president of the an educator who began as a economic and industrial new photos will be Tuesdays I'nion County (educational appointed to the superin- development programs in Prior to joining First Congress in the 12th. classroom teacher 28 years tendancy at the Board's from 7 to 9 p.m. on March 20, Services Commission ago and has served as a New Jersey for the past 14 Jersey National he served congressional district, April «, 23, May 14, 2IS.
    [Show full text]
  • Y's Men to Fix Elm St. Field
    (908) 232-4407 USPS 680020 Thursday, November 21, 2002 Published Every Thursday Since 1890 OUR 113th YEAR – ISSUE NO. 11-113 Periodical – Postage Paid at Westfield, N.J. www.goleader.com [email protected] FIFTY CENTS BOE Audit Runs Smoothly; Y’s Men to Fix Elm St. Field By CHARLOTTE LEDERMAN sional Greg Nicoll also proposed to tunate here in Westfield that the level Specially Written for The Westfield Leader “establish and manage a field condi- of cooperation and support is so great. “No violation of state laws, regu- tioning program of aeration, fertili- We all celebrate the achievements in lations, no reportable conditions.” zation and seeding for the Elm Street our schools and commit to working Such was the good news at Tuesday’s Field.” together to help our children suc- board of education meeting as the The service group believes that ceed.” Highland Park accounting firm of “this conditioning program will sig- The board also wished to con- Hodulik and Morrison, PA gave their nificantly improve the condition of gratulate the Westfield High School report on the 2001-2002 audit. the field and its turf within a short Girls Varsity Soccer team on win- Indeed, accountant Bob Morrison period.” It will work in conjunction ning the North Jersey Section 2 further informed the board that his with numerous suppliers and ser- Championship on Monday. firm had found that “the financial vices to “directly assist the board in Mrs. Gardner reminded the board statements were fairly represented” covering the costs and managing the that the football team will play on and the internal controls of checks program.” Thanksgiving Day in Plainfield, and balances were “designed prop- Board President Arlene Gardner “marking more than 100 years of erly and working.” accepted the Y’s Men’s proposal, rivalry between the two schools.” Mr.
    [Show full text]
  • Update Covers C1-C4 Iss2 2005.Indd
    In Compliance and In Court by John B. Reiss, Ph.D., and William M. Janssen his article examines various fraud and abuse cases is the simultane- violated the Anti-Kickback Statute. Tlegal issues facing the medical ous fi ling of False Claims Act charges. Under the government’s theory, these device, pharmaceutical, and biologics Because the False Claims Act permits inducements resulted in an illegal use industries; court decisions or settle- fi nes of up to three times the amount of the drugs, and claims fi led for these ments over the past year; and suggested of the claim—and penalties of between uses were thus false. Also brought actions. New guidelines set standards $5,500 and $11,000 per claim—penal- into focus by this case were the False that industry leaders should consider as ties can add up quickly to billions of Claims Act’s qui tam provisions, which they plan product development, sales, dollars, giving the government an enor- allow whistleblowers to participate in and marketing strategies. mous “hammer” with which to exact up to 25% of the government’s recov- settlements. ery. A majority of the recent cases have Fraud and Abuse and the The complexity of the application resulted from whistleblower fi lings. False Claims Act of these laws is demonstrated by the TAP Pharmaceuticals made an Fraud and abuse issues dominated Warner-Lambert case.1 The primary $875 million payment in October 2001, the headlines during 2004. The U.S. allegation involved the company’s partly as the result of its guilty plea for Attorney and the Department of Health off-label marketing of its epilepsy violating the Prescription Drug Market- and Human Services (DHHS) Offi ce of drug, Neurontin®, in violation of the ing Act.2 The government also alleged Inspector General (OIG) continued a Federal Food, Drug, and Cosmetic Act manipulation of the average wholesale high level of activity, and states’ attor- (FDCA).
    [Show full text]